<DOC>
	<DOC>NCT01551602</DOC>
	<brief_summary>The objective of this study is to investigate the pharmacokinetics, safety, and tolerability of AK159 administered to healthy postmenopausal women.</brief_summary>
	<brief_title>Clinical Study of AK159 in Healthy Postmenopausal Women</brief_title>
	<detailed_description>This study consists of Part 1 and Part 2. &lt;Part 1&gt; Part 1 will be conducted according to a single-centre, randomized, single-dose, 3-period, 5-treatment alternating crossover design in two groups of healthy post-menopausal women The pharmacokinetics, safety, and tolerability of a single dose of AK159 (4 levels) will be investigated versus teriparatide acetate for injection as a control. &lt;Part 2&gt; Part 2 will be conducted according to a multiple-centre, randomized, double-blind, placebo-controlled, repeated dose parallel design of healthy post-menopausal women The pharmacokinetics, safety, and tolerability of AK159 (4 levels) for 8 weeks will be investigated versus teriparatide acetate for injection and placebo as controls. Pharmacokinetics, safety, and tolerability following long-term application will also be investigated.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Healthy postmenopausal ethnic Japanese women; At least 45 years of age at the time consent is obtained; and Give voluntary consent in writing with a sufficient understanding of the study. Clinical abnormality identified in the laboratory tests Weight &lt; 40.0 kg Body mass index &lt; 17.5 or &gt;=30.5 History of disease of the kidneys, liver, heart, brain, or other organ that makes them ineligible as subjects Previously received radiation treatment potentially affecting bone Systolic blood pressure &lt; 90 mmHg QTc exceeds 470 msec in a 12lead electrocardiography Serum calcium level exceeding 10.4 mg/dL History of contact dermatitis or skin disease potentially compromising study evaluation Used drugs which impact bone metabolism in the 8week period preceding investigational product administration Used a bisphosphonate; Used a teriparatide product;</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>AK159</keyword>
	<keyword>teriparatide acetate</keyword>
</DOC>